"My Current Longevity Stack" — Tim Ferriss

Why this is in the vault

Tim's actual self-administered protocol is signal for the longevity-curious-affluent buyer profile that overlaps with the Diamandis audience. Connects directly to [[01-projects/investing/candidates/longevity-roster-2026-05]] (Diamandis longevity report) as a demand-side cross-check: the conservative-stack headline (vitamin D + creatine + intermittent rapamycin/urolithin A experimentation) tells us anything outside that orbit will struggle for adoption from this segment. Useful as a market-sizing prior on what longevity-curious affluent buyers actually consume.

Episode summary

Short clip from a longer Tim Ferriss interview (host appears to be a tech/longevity-curious operator, possibly Sam Altman or similar — not explicitly named in extracted captions). The host opens by noting how the quantified-self scene grew from 12 people in Kevin Kelly's house in ~2008 to "armies of tens of thousands of self-described biohackers." Asks Tim where he's actually landed for himself. Tim's headline answer: he's far more conservative than people would assume. The basics (sleep, exercise, diet) "collapse" most of the value; he's mostly waiting for "the real drugs to come out." Conversation drifts into rapamycin pulsing, urolithin A, mitochondrial-health interest, fasting protocols, and a longer riff on "rebooting" the brain (anesthesia, stellate ganglion block, ibogaine flood-dosing for opiate addiction, non-invasive brain stimulation).

Key arguments / segments

• No biological free lunch. Simplistic but useful heuristic; saves you from a lot of pitfalls (questionable gene therapy, follistatin trips abroad, etc.).
• The basics dominate. Sleep, exercise, eat well. Most of the rest is small additive value.
• Waiting on real drugs. Most interesting interventions for him are still in the pipeline (eye-lens-focusing eye drops, neurosensory aging fixes). Would fund startups in neurosensory + cosmetics-of-aging space.
• Cosmetic-aging supplements are massively under-served. Funded a Stanford clinical trial on this. Sees peptides as largely cosmetic in nature for many users.
• Rapamycin is interesting with asterisks. Immunosuppressant; can hurt you if you don't know what you're doing. Considering combining with Norwegian 4x4 interval training to look at hippocampal volume changes.
• Mitochondrial health bias. Drives interest in urolithin A, intermittent fasting, occasional 3-7 day fasts (fast-mimicking, per Dom D'Agostino input) for autophagy/mitophagy — but not all the time.
• Family history drives focus. Alzheimer's, Parkinson's in family, including AOE3/3 cases. Keen on cerebrovascular interventions; experimenting with ketone esters and salts.
• General anesthesia is over-prescribed. "Follow the money" — it's a huge line item. Personality changes, memory issues post-op are under-discussed. Just had local-anesthesia-only minor surgery instead.
• Brain "reboot" frontier. Bioelectric medicine and non-invasive brain stimulation is "one of the great next frontiers" for psychiatric conditions and performance enhancement. Sees outpatient procedures (1-2 hour visits) as the future shape, not pills/IVs.
• Ibogaine is the most interesting reboot precedent he's seen. Flood-dosing for opiate addicts, plus Nolan Williams' work on apparent brain-age reversal in TBI veterans (likely GDNF/BDNF pathway).

Notable claims (specific products/protocols/dosages mentioned)

• Tim's actual current stack (the short list): vitamin D + creatine. That's it for daily basics.
• Watch / experimenting with:
  • Rapamycin (pulsed dosing) — possibly stacked with Norwegian 4x4 HIIT
  • Urolithin A — "data keeps mounting"
  • Ketone esters and salts — for cerebrovascular benefit
  • Intermittent fasting + occasional 3-7 day fasts (fast-mimicking diet variant)
  • Obicetrapib — "one to keep an eye on, not yet ready for prime time"
• Caution flags:
  • Magnesium absorption inhibited by omeprazole (which he takes); coadminister magnesium with certain protocols
  • Photobiomodulation (PBM) through the eyes is interesting; transcranial PBM gets a "note of caution"
  • Stellate ganglion block — interesting for very specific use cases
• Ibogaine flood-dosing for opiate addiction: relatively high doses, medical supervision, magnesium co-admin, real risk of fatal cardiac events. Howard Lotsoff lineage.
• Cosmetic peptides mentioned in passing: 5-HKCu, melatonin (described as "basically cosmetic in nature" for many use cases)
• Won't touch: unsupervised gene therapy tourism, follistatin via foreign clinics

Guests (if any)

Tim Ferriss is the interviewee. The host is not explicitly named in the auto-captions but speaks in a tech-investor cadence (references quantified-self origins, asks about ADHD/autism overdiagnosis incentives, jokes about "rebooting" the body like a laptop). Likely from a tech/longevity podcast — host identity not load-bearing for the takeaways.

Mapping against Ray Data Co — likely medium

Connects to [[01-projects/investing/candidates/longevity-roster-2026-05]] (Diamandis longevity report). Cross-check Tim's actual consumption against the roster:

• Rapamycin Rx market: Tim is actively pulsing rapamycin. The roster flags "rapamycin Rx market" as partially-mentioned but not surfaced as an investable name. Tim's continued interest is a soft confirm that the affluent-biohacker demand side is real.
• Urolithin A: Tim says "the data keeps mounting." Timeline Nutrition (Mitopure) is the obvious commercial player — worth a roster check; if not on the roster, it should be added as a candidate given Diamandis-tier biohacker validation.
• Ketone esters/salts: KetoneIQ / HVMN / Ketone-IQ space. Worth a roster check.
• GLP-1s: mentioned as a "reboot" example for impulse-control changes (smoking, drinking) — confirms broad-spectrum behavioral impact thesis already in the public discourse.
• Bioelectric / non-invasive brain stim: Tim names this as "one of the great next frontiers." Relevant to roster's neuroscience/longevity adjacent segment. Worth surfacing names like Neuralink-adjacent non-invasive players (Neurable, Flow Neuroscience, etc.) as a future-watch.

Tim's stack is signal: this is what the longevity-curious-affluent buyer (his audience overlap with Diamandis's audience is substantial) actually puts in their body. The headline is conservative — vitamin D + creatine + intermittent rapamycin/urolithin A experimentation. Anything outside that orbit will struggle to get adoption from this segment.

Medium mapping: not a direct investment thesis, but a useful validate-the-demand-side cross-check on the roster. Good for the "what do longevity-curious affluent buyers actually consume" market-sizing prior.

Related

• [[01-projects/investing/candidates/longevity-roster-2026-05]]
• [[06-reference/transcripts/2026-05-11-tim-ferriss-current-longevity-stack-transcript]]